Biologics and the cardiovascular system: A double-edged sword

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2013, Pages 68-82

  Roubille, Camille ^a   Martel Pelletier, Johanne ^a   Haraoui, Boulos ^a   Tardif, Jean Claude ^b   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Atherosclerosis; Biologics; Cardiovascular disease; Cytokines; Heart failure; IL 1; IL 6; Inflammation; TNF alpha

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VINCRISTINE;

ADD ON THERAPY; AORTA ARCH SYNDROME; APOPTOSIS; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; BEHCET DISEASE; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR ACCIDENT; CHRONIC ARTHRITIS; DAS28; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; EYE INJURY; FLUSHING; GIANT CELL ARTERITIS; HEADACHE; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; INFLAMMATION; INTESTINE ULCER; METABOLIC SYNDROME X; MICROSCOPIC POLYANGIITIS; MYOCARDITIS; NAUSEA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; PSORIASIS; PULMONARY VASCULITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA VASCULITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TACHYCARDIA; UVEITIS; VASCULAR DISEASE; VISUAL ACUITY; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 84875862913     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/1871523011312010009     Document Type: Review

References (136)

1. Solomon, D. H.; Karlson, E. W.; Rimm, E. B.; Cannuscio, C. C.; Mandl, L. A.; Manson, J. E.; Stampfer, M. J.; Curhan, G. C. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation, 2003, 107(9), 1303-1307.
2. Nicola, P. J.; Maradit-Kremers, H.; Roger, V. L.; Jacobsen, S. J.; Crowson, C. S.; Ballman, K. V.; Gabriel, S. E. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum., 2005, 52(2), 412-420.
3. Maradit-Kremers, H.; Nicola, P. J.; Crowson, C. S.; Ballman, K. V.; Gabriel, S. E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis rheum., 2005, 52(3), 722-732.
4. Wolfe, F.; Freundlich, B.; Straus, W. L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J. Rheumatol., 2003,30 (1), 36-40.
5. del Rincon, I. D.; Williams, K.; Stern, M. P.; Freeman, G. L.; Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum., 2001, 44(12), 2737-2745.
6. Ridker, P. M.; Hennekens, C. H.; Buring, J. E.; Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med., 2000, 342(12), 836-843.
7. Ridker, P. M.; Danielson, E.; Fonseca, F. A.; Genest, J.; Gotto, A. M. Jr.; Kastelein, J. J.; Koenig, W.; Libby, P.; Lorenzatti, A. J.; MacFadyen, J. G.; Nordestgaard, B. G.; Shepherd, J.; Willerson, J. T.; Glynn, R. J.; Group, J. S. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 2008, 359(21), 2195-2207.
8. Ridker, P. M.; Danielson, E.; Fonseca, F. A.; Genest, J.; Gotto, A. M. Jr.; Kastelein, J. J.; Koenig, W.; Libby, P.; Lorenzatti, A. J.; Macfadyen, J. G.; Nordestgaard, B. G.; Shepherd, J.; Willerson, J. T.; Glynn, R. J.; Group, J. T. S. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 2009, 373(9670), 1175-1182.
9. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352(16), 1685-1695.
10. Bartoloni, E.; Alunno, A.; Bistoni, O.; Gerli, R. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun. rev., 2010, 9 (10), 701-707.
11. Peters, M. J.; Symmons, D. P.; McCarey, D.; Dijkmans, B. A.; Nicola, P.; Kvien, T. K.; McInnes, I. B.; Haentzschel, H.; Gonzalez-Gay, M. A.; Provan, S.; Semb, A.; Sidiropoulos, P.; Kitas, G.; Smulders, Y. M.; Soubrier, M.; Szekanecz, Z.; Sattar, N.; Nurmohamed, M. T. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis., 2010, 69(2), 325-331.
12. Listing, J.; Strangfeld, A.; Kekow, J.; Schneider, M.; Kapelle, A.; Wassenberg, S.; Zink, A. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum., 2008, 58(3), 667-677.
13. Jacobsson, L. T.; Turesson, C.; Gulfe, A.; Kapetanovic, M. C.; Petersson, I. F.; Saxne, T.; Geborek, P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol., 2005, 32(7), 1213-1218.
14. Bernatsky, S.; Hudson, M.; Suissa, S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology, 2005, 44(5), 677-680.
15. Wolfe, F.; Michaud, K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med., 2004, 116(5), 305-311.
16. Lunt, M.; Watson, K. D.; Dixon, W. G.; Symmons, D. P.; Hyrich, K. L. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum., 2010, 62(11), 3145-3153.
17. Szekanecz, Z.; Kerekes, G.; Der, H.; Sandor, Z.; Szabo, Z.; Vegvari, A.; Simkovics, E.; Soos, L.; Szentpetery, A.; Besenyei, T.; Szucs, G.; Szanto, S.; Tamasi, L.; Szegedi, G.; Shoenfeld, Y.; Soltesz, P. Accelerated atherosclerosis in rheumatoid arthritis. Ann. N. Y. Acad. Sci., 2007, 1108, 349-358.
18. Kerekes, G.; Szekanecz, Z.; Der, H.; Sandor, Z.; Lakos, G.; Muszbek, L.; Csipo, I.; Sipka, S.; Seres, I.; Paragh, G.; Kappelmayer, J.; Szomjak, E.; Veres, K.; Szegedi, G.; Shoenfeld, Y.; Soltesz, P. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol., 2008, 35(3), 398-406.
19. Sprague, A. H.; Khalil, R. A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol., 2009, 78(6), 539-552.
20. Del Porto, F.; Lagana, B.; Lai, S.; Nofroni, I.; TInterni, F.; Vitale, M.; Podesta, E.; Mitterhofer, A. P.; D'Amelio, R. Response to antitumour necrosis factor alpha blockade is associated with reduction of carotid Internima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford), 2007, 46(7), 1111-1115.
21. Szekanecz, Z.; Kerekes, G.; Soltesz, P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat. Rev. Rheumatol., 2009, 5 (12), 677-684.
22. Wong, M.; Oakley, S. P.; Young, L.; Jiang, B. Y.; Wierzbicki, A.; Panayi, G.; Chowienczyk, P.; Kirkham, B. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2009, 68(8), 1277-1284.
23. Galarraga, B.; Khan, F.; Kumar, P.; Pullar, T.; Belch, J. J. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford), 2009, 48(11), 1418-1423.
24. Maki-Petaja, K. M.; Hall, F. C.; Booth, A. D.; Wallace, S. M.; Yasmin; Bearcroft, P. W.; Harish, S.; Furlong, A.; McEniery, C. M.; Brown, J.; Wilkinson, I. B. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation, 2006, 114(11), 1185-1192.
25. Channual, J.; Wu, J. J.; Dann, F. J. Effects of tumor necrosis factoralpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol. Ther., 2009, 22(1), 61-73.
26. Seta, Y.; Shan, K.; Bozkurt, B.; Oral, H.; Mann, D. L. Basic mechanisms in heart failure: the cytokine hypothesis. J. Cardiac. Failure, 1996, 2(3), 243-249.
27. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H. M.; Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med., 1990, 323(4), 236-2341.
28. McMurray, J.; Abdullah, I.; Dargie, H. J.; Shapiro, D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br. Heart J., 1991, 66(5), 356-358.
29. Bozkurt, B.; Kribbs, S. B.; Clubb, F. J. Jr.; Michael, L. H.; Didenko, V. V.; Hornsby, P. J.; Seta, Y.; Oral, H.; Spinale, F. G.; Mann, D. L. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation, 1998, 97(14), 1382-1391.
30. Chen, D.; Assad-Kottner, C.; Orrego, C.; Torre-Amione, G. Cytokines and acute heart failure. Crit. Care Med., 2008, 36(1 Suppl), S9-16.
31. Nakano, M.; Knowlton, A. A.; Dibbs, Z.; Mann, D. L. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation, 1998, 97(14), 1392-1400.
32. Flaherty, M. P.; Guo, Y.; Tiwari, S.; Rezazadeh, A.; Hunt, G.; Sanganalmath, S. K.; Tang, X. L.; Bolli, R.; Dawn, B. The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. J. Mol. Cell. Cardiol., 2008, 45 (6), 735-741.
33. Lecour, S.; Smith, R. M.; Woodward, B.; Opie, L. H.; Rochette, L.; Sack, M. N. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J. Mol. Cell. Card., 2002, 34 (5), 509-518.
34. Schulz, R.; Heusch, G. Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction? Circulation, 2009, 119(10), 1355-1357.
35. Deuchar, G. A.; Opie, L. H.; Lecour, S. TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning. Life Sci., 2007, 80(18), 1686-1691.
36. Smith, R. M.; Suleman, N.; McCarthy, J.; Sack, M. N. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFalpha gene. Cardiovasc. Res., 2002, 55 (3), 553-560.
37. Lecour, S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J. Mol. Cell. Cardiol., 2009, 47(1), 32-40.
38. Lecour, S.; James, R. W. When are pro-inflammatory cytokines SAFE in heart failure? Eur. Heart J., 2011, 32(6), 680-685.
39. Hattori, R.; Maulik, N.; Otani, H.; Zhu, L.; Cordis, G.; Engelman, R. M.; Siddiqui, M. A.; Das, D. K. Role of STAT3 in ischemic preconditioning. J. Mol. Cell. Cardiol., 2001, 33(11), 1929-1936.
40. Boengler, K.; Hilfiker-Kleiner, D.; Heusch, G.; Schulz, R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res. Cardiol.,2010, 105(6), 771-785.
41. Podewski, E. K.; Hilfiker-Kleiner, D.; Hilfiker, A.; Morawietz, H.; Lichtenberg, A.; Wollert, K. C.; Drexler, H. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation, 2003, 107(6), 798-802.
42. Hilfiker-Kleiner, D.; Kaminski, K.; Podewski, E.; Bonda, T.; Schaefer, A.; Sliwa, K.; Forster, O.; QuIntern, A.; Landmesser, U.; Doerries, C.; Luchtefeld, M.; Poli, V.; Schneider, M. D.; Balligand, J. L.; Desjardins, F.; Ansari, A.; Struman, I.; Nguyen, N. Q.; Zschemisch, N. H.; Klein, G.; Heusch, G.; Schulz, R.; Hilfiker, A.; Drexler, H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 2007, 128(3), 589-600.
43. Jacoby, J. J.; Kalinowski, A.; Liu, M. G.; Zhang, S. S.; Gao, Q.; Chai, G. X.; Ji, L.; Iwamoto, Y.; Li, E.; Schneider, M.; Russell, K. S.; Fu, X. Y. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc. Natl. Acad. Sci. U SA, 2003, 100(22), 12929-12934.
44. Hamid, T.; Gu, Y.; Ortines, R. V.; Bhattacharya, C.; Wang, G.; Xuan, Y. T.; Prabhu, S. D. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation, 2009, 119(10), 1386-1397.
45. Kadokami, T.; Frye, C.; Lemster, B.; Wagner, C. L.; Feldman, A. M.; McTiernan, C. F. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation, 2001, 104(10), 1094-1097.
46. Deswal, A.; Bozkurt, B.; Seta, Y.; Parilti-Eiswirth, S.; Hayes, F. A.; Blosch, C.; Mann, D. L. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation, 1999, 99(25), 3224-3226.
47. Bozkurt, B.; Torre-Amione, G.; Warren, M. S.; Whitmore, J.; Soran, O. Z.; Feldman, A. M.; Mann, D. L. Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation, 2001, 103(8), 1044-1047.
48. Mann, D. L.; McMurray, J. J.; Packer, M.; Swedberg, K.; Borer, J. S.; Colucci, W. S.; Djian, J.; Drexler, H.; Feldman, A.; Kober, L.; Krum, H.; Liu, P.; Nieminen, M.; Tavazzi, L.; van Veldhuisen, D. J.; Waldenstrom, A.; Warren, M.; Westheim, A.; Zannad, F.; Fleming, T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation, 2004, 109(13), 1594-1602.
49. Chung, E. S.; Packer, M.; Lo, K. H.; Fasanmade, A. A.; Willerson, J. T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation, 2003, 107(25), 3133-3140.
50. Cacciapaglia, F.; Navarini, L.; Menna, P.; Salvatorelli, E.; Minotti, G.; Afeltra, A. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun. Rev., 2011, 10(10), 631-635.
51. Yang, J.; Hossein Noyan-Ashraf, M.; Meissner, A.; Voigtlaender-Bolz, J.; Kroetsch, J. T.; Foltz, W.; Jaffray, D.; Kapoor, A.; Momen, A.; Heximer, S. P.; Zhang, H.; van Eede, M.; Henkelman, R. M.; Matthews, S. G.; Lidington, D.; Husain, M.; Bolz, S. S. Proximal cerebral arteries develop myogenic responsiveness in heart failure via tumor necrosis factor-alpha-dependent activation of sphingosine-1-phosphate signaling. Circulation, 2012, 126(2), 196-206.
52. Melikoglu, M.; Fresko, I.; Mat, C.; Ozyazgan, Y.; Gogus, F.; Yurdakul, S.; Hamuryudan, V.; Yazici, H. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J. Rheumatol., 2005, 32(1), 98-105.
53. Wechsler, B.; Sable-Fourtassou, R.; Bodaghi, B.; Huong, D. L.; Cassoux, N.; Badelon, I.; Fain, O.; LeHoang, P.; Piette, J. C. Infliximab in refractory uveitis due to Behcet's disease. Clin. Exp. Rheumatol., 2004, 22(4 Suppl 34), S14-16.
54. Lindstedt, E. W.; Baarsma, G. S.; Kuijpers, R. W.; van Hagen, P. M. Anti-TNF-alpha therapy for sight threatening uveitis. Br. J. Ophthalmol., 2005, 89 (5), 533-536.
55. Sfikakis, P. P.; Kaklamanis, P. H.; Elezoglou, A.; Katsilambros, N.; Theodossiadis, P. G.; Papaefthimiou, S.; Markomichelakis, N. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann. Intern Med., 2004, 140 (5), 404-406.
56. Ohno, S.; Nakamura, S.; Hori, S.; Shimakawa, M.; Kawashima, H.; Mochizuki, M.; Sugita, S.; Ueno, S.; Yoshizaki, K.; Inaba, G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J. Rheumatol., 2004, 31 (7), 1362-1368.
57. Tugal-Tutkun, I.; Mudun, A.; Urgancioglu, M.; Kamali, S.; Kasapoglu, E.; Inanc, M.; Gul, A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum., 2005, 52(8), 2478-2484.
58. Giardina, A.; Ferrante, A.; Ciccia, F.; Vadala, M.; Giardina, E.; Triolo, G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. Rheumatol. Intern., 2011, 31(1), 33-37.
59. Yamada, Y.; Sugita, S.; Tanaka, H.; Kamoi, K.; Kawaguchi, T.; Mochizuki, M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br. J. Ophthalmol., 2010, 94(3), 284-288.
60. Markomichelakis, N.; Delicha, E.; Masselos, S.; Fragiadaki, K.; Kaklamanis, P.; Sfikakis, P. P. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4-week study. Rheumatology (Oxford), 2011, 50(3), 593-597.
61. Sfikakis, P. P.; Markomichelakis, N.; Alpsoy, E.; Assaad-Khalil, S.; Bodaghi, B.; Gul, A.; Ohno, S.; Pipitone, N.; Schirmer, M.; Stanford, M.; Wechsler, B.; Zouboulis, C.; Kaklamanis, P.; Yazici, H. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford), 2007, 46(5), 736-741.
62. Arida, A.; Fragiadaki, K.; Giavri, E.; Sfikakis, P. P. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin. Arthritis Rheum., 2011, 41(1), 61-70.
63. Iwata, S.; Saito, K.; Yamaoka, K.; Tsujimura, S.; Nawata, M.; Suzuki, K.; Tanaka, Y. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford), 2009, 48(8), 1012-1013.
64. Perra, D.; Alba, M. A.; Callejas, J. L.; Mesquida, M.; Rios-Fernandez, R.; Adan, A.; Ortego, N.; Cervera, R.; Espinosa, G. Adalimumab for the treatment of Behcet's disease: experience in 19 patients. Rheumatology (Oxford), 2012, 51(10), 1825-1831.
65. Olivieri, I.; Leccese, P.; D'Angelo, S.; Padula, A.; Nigro, A.; Palazzi, C.; Coniglio, G.; Latanza, L. Efficacy of adalimumab in patients with Behcet's disease unsuccessfully treated with infliximab. Clin. Exp. Rheumatol., 2011, 29(4 Suppl 67), p. S54-57.
66. Buonuomo, P. S.; Bracaglia, C.; Campana, A.; Insalaco, A.; Pardeo, M.; Cortis, E.; Ugazio, A. G. Infliximab therapy in pediatric Takayasu's arteritis: report of two cases. Rheumatol. Intern., 2011, 31(1), 93-95.
67. Filocamo, G.; Buoncompagni, A.; Viola, S.; Loy, A.; Malattia, C.; Ravelli, A.; Martini, A. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J. Pediatr., 2008, 153(3), 432-434.
68. Comarmond, C.; Plaisier, E.; Dahan, K.; Mirault, T.; Emmerich, J.; Amoura, Z.; Cacoub, P.; Saadoun, D. Anti TNF-alpha in refractory Takayasu's arteritis: Cases series and review of the literature. Autoimmun. Rev., 2012, 11 (9), 678-684.
69. Mekinian, A.; Neel, A.; Sibilia, J.; Cohen, P.; Connault, J.; Lambert, M.; Federici, L.; Berthier, S.; Fiessinger, J. N.; Godeau, B.; Marie, I.; Guillevin, L.; Hamidou, M.; Fain, O. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford), 2012, 51 (5), 882-886.
70. Schmidt, J.; Kermani, T. A.; Bacani, A. K.; Crowson, C. S.; Matteson, E. L.; Warrington, K. J. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. Arthritis Care Res. (Hoboken), 2012, 64(7), 1079-1083.
71. Andonopoulos, A. P.; Meimaris, N.; Daoussis, D.; Bounas, A.; Giannopoulos, G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann. Rheum. Dis., 2003, 62(11), 1116.
72. Cantini, F.; Niccoli, L.; Salvarani, C.; Padula, A.; Olivieri, I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum., 2001, 44(12), 2933-2935.
73. Airo, P.; Antonioli, C. M.; Vianelli, M.; Toniati, P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford), 2002, 41(3), 347-349.
74. Tan, A. L.; Holdsworth, J.; Pease, C.; Emery, P.; McGonagle, D. Successful treatment of resistant giant cell arteritis with etanercept. Ann. Rheum. Dis., 2003, 62 (4), 373-374.
75. Ahmed, M. M.; Mubashir, E.; Hayat, S.; Fowler, M.; Berney, S. M. Treatment of refractory temporal arteritis with adalimumab. Clin. Rheumatol., 2007, 26(8), 1353-1355.
76. Hoffman, G. S.; Cid, M. C.; Rendt-Zagar, K. E.; Merkel, P. A.; Weyand, C. M.; Stone, J. H.; Salvarani, C.; Xu, W.; Visvanathan, S.; Rahman, M. U. Infliximab for maInternenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann. Intern. Med., 2007, 146(9), 621-630.
77. Martinez-Taboada, V. M.; Rodriguez-Valverde, V.; Carreno, L.; Lopez-Longo, J.; Figueroa, M.; Belzunegui, J.; Mola, E. M.; Bonilla, G. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis., 2008, 67(5), 625-630.
78. Booth, A.; Harper, L.; Hammad, T.; Bacon, P.; Griffith, M.; Levy, J.; Savage, C.; Pusey, C.; Jayne, D. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibodyassociated systemic vasculitis. J. Am. Soc. Nephrol., 2004, 15(3), 717-721.
79. Bartolucci, P.; Ramanoelina, J.; Cohen, P.; Mahr, A.; Godmer, P.; Le Hello, C.; Guillevin, L. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford), 2002, 41(10), 1126-1132.
80. Josselin, L.; Mahr, A.; Cohen, P.; Pagnoux, C.; Guaydier-Souquieres, G.; Hayem, G.; Job-Deslandre, C.; Liferman, F.; Pourrat, J.; Guillevin, L. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann. Rheum. Dis. 2008, 67(9), 1343-6.
81. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med., 2005, 352(4), 351-361.
82. Kawashiri, S. Y.; Kawakami, A.; Yamasaki, S.; Imazato, T.; Iwamoto, N.; Fujikawa, K.; Aramaki, T.; Tamai, M.; Nakamura, H.; Ida, H.; Origuchi, T.; Ueki, Y.; Eguchi, K. Effects of the anti-Internerleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol. Intern., 2011, 31(4), 451-456.
83. Koike, T.; Harigai, M.; Inokuma, S.; Ishiguro, N.; Ryu, J.; Takeuchi, T.; Takei, S.; Tanaka, Y.; Ito, K.; Yamanaka, H. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Internerim analysis of 3881 patients. Ann. Rheum. Dis., 2011, 70(12), 2148-2151.
84. Schiff, M. H.; Kremer, J. M.; Jahreis, A.; Vernon, E.; Isaacs, J. D.; van Vollenhoven, R. F. Internegrated safety in tocilizumab clinical trials. Arthritis Res. Ther., 2011, 13(5), R141.
85. Kume, K.; Amano, K.; Yamada, S.; Hatta, K.; Ohta, H.; Kuwaba, N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J. Rheumatol., 2011, 38(10), 2169-2171.
86. Protogerou, A. D.; Zampeli, E.; Fragiadaki, K.; Stamatelopoulos, K.; Papamichael, C.; Sfikakis, P. P. A pilot study of endothelial dysfunction and aortic stiffness after Internerleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis, 2011, 219(2), 734-736.
87. Ridker, P. M.; Rifai, N.; Stampfer, M. J.; Hennekens, C. H. Plasma concentration of Internerleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 2000, 101(15), 1767-1772.
88. Danesh, J.; Kaptoge, S.; Mann, A. G.; Sarwar, N.; Wood, A.; Angleman, S. B.; Wensley, F.; Higgins, J. P.; Lennon, L.; Eiriksdottir, G.; Rumley, A.; Whincup, P. H.; Lowe, G. D.; Gudnason, V. Long-term Internerleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med., 2008, 5(4), e78.
89. Hingorani, A. D.; Casas, J. P. The Internerleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, 2012, 379(9822), 1214-1224.
90. Salvarani, C.; Magnani, L.; Catanoso, M.; Pipitone, N.; Versari, A.; Dardani, L.; Pulsatelli, L.; Meliconi, R.; Boiardi, L. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford), 2012, 51(1), 151-156.
91. Unizony, S.; Arias-Urdaneta, L.; Miloslavsky, E.; Arvikar, S.; Khosroshahi, A.; Keroack, B.; Stone, J. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. (Hoboken), 2012, 64(11), 1720-1729.
92. Cohen, S. B.; Emery, P.; Greenwald, M. W.; Dougados, M.; Furie, R. A.; Genovese, M. C.; Keystone, E. C.; Loveless, J. E.; Burmester, G. R.; Cravets, M. W.; Hessey, E. W.; Shaw, T.; Totoritis, M. C. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum., 2006, 54(9), 2793-2806.
93. Nikolaidis, L. A. When cancer and heart failure cross paths: a case report of severe cardiorenal compromise associated with the anti-CD20 monoclonal antibody rituximab in a patient with dilated cardiomyopathy. Congestive Heart Failure, 2001, 7(4), 223-227.
94. Kanamori, H.; Tsutsumi, Y.; Mori, A.; Kawamura, T.; Obara, S.; Shimoyama, N.; Tanaka, J.; Asaka, M.; Imamura, M.; Masauzi, N. Delayed reduction in left ventricular function following treatment of non-Hodgkin's lymphoma with chemotherapy and rituximab, unrelated to acute infusion reaction. Cardiology, 2006, 105(3), 184-187.
95. Millward, P. M.; Bandarenko, N.; Chang, P. P.; Stagg, K. F.; Afenyi-Annan, A.; Hay, S. N.; Brecher, M. E. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion, 2005, 45(9), 1481-1486.
96. Arunprasath, P.; Gobu, P.; Dubashi, B.; Satheesh, S.; Balachander, J. Rituximab induced myocardial infarction: A fatal drug reaction. J. Cancer Res. Ther., 2011, 7(3), 346-348.
97. Kilickap, S.; Yavuz, B.; Aksoy, S.; Sahiner, L.; Dincer, M.; Harputluoglu, H.; Erman, M.; Aytemir, K.; Tokgozoglu, L.; Barista, I. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. Med. Oncol., 2008, 25(4), 437-442.
98. Siano, M.; Lerch, E.; Negretti, L.; Zucca, E.; Rodriguez-Abreu, D.; Oberson, M.; Leoncini, L.; Mora, O.; Sessa, C.; Gallino, A.; Ghielmini, M. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin. Cancer Res., 2008, 14(23), 7935-7939.
99. Gonzalez-Juanatey, C.; Llorca, J.; Vazquez-Rodriguez, T. R.; Diaz-Varela, N.; Garcia-Quiroga, H.; Gonzalez-Gay, M. A. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum., 2008, 59(12), 1821-1824.
100. Kerekes, G.; Soltesz, P.; Der, H.; Veres, K.; Szabo, Z.; Vegvari, A.; Szegedi, G.; Shoenfeld, Y.; Szekanecz, Z. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin. Rheumatol., 2009, 28(6), 705-710.
101. Mathieu, S.; Pereira, B.; Dubost, J. J.; Lusson, J. R.; Soubrier, M. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford), 2012, 51(6), 1107-1111.
102. Stone, J. H.; Merkel, P. A.; Spiera, R.; Seo, P.; Langford, C. A.; Hoffman, G. S.; Kallenberg, C. G.; St Clair, E. W.; Turkiewicz, A.; Tchao, N. K.; Webber, L.; Ding, L.; Sejismundo, L. P.; Mieras, K.; Weitzenkamp, D.; Ikle, D.; Seyfert-Margolis, V.; Mueller, M.; Brunetta, P.; Allen, N. B.; Fervenza, F. C.; Geetha, D.; Keogh, K. A.; Kissin, E. Y.; Monach, P. A.; Peikert, T.; Stegeman, C.; Ytterberg, S. R.; Specks, U. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med., 2010, 363(3) 221-232.
103. Jones, R. B.; Tervaert, J. W.; Hauser, T.; Luqmani, R.; Morgan, M. D.; Peh, C. A.; Savage, C. O.; Segelmark, M.; Tesar, V.; van Paassen, P.; Walsh, D.; Walsh, M.; Westman, K.; Jayne, D. R. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med., 2010 363(3), 211-220.
104. Guerry, M. J.; Brogan, P.; Bruce, I. N.; D'Cruz, D. P.; Harper, L.; Luqmani, R.; Pusey, C. D.; Salama, A. D.; Scott, D. G.; Savage, C. O.; Watts, R. A.; Jayne, D. R. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford), 2012, 51(4), 634-643.
105. Guillevin, L.; Mahr, A. New horizons for treatment of ANCAassociated vasculitides. Rheumatology (Oxford), 2012, 51(4), 583-584.
106. Smith, R. M.; Jones, R. B.; Guerry, M. J.; Laurino, S.; Catapano, F.; Chaudhry, A.; Smith, K. G.; Jayne, D. R. Rituximab for remission maInternenance in relapsing ANCA-associated vasculitis. Arthritis Rheum., 2012, 64(11), p. 3760-3769
107. Vicenova, B.; Vopalensky, V.; Burysek, L.; Pospisek, M. Emerging role of Internerleukin-1 in cardiovascular diseases. Physiol. Res., 2009, 58(4), 481-498.
108. Galea, J.; Armstrong, J.; Gadsdon, P.; Holden, H.; Francis, S. E.; Holt, C. M. Internerleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb. Vasc. Biol., 1996, 16(8), 1000-1006.
109. Kirii, H.; Niwa, T.; Yamada, Y.; Wada, H.; Saito, K.; Iwakura, Y.; Asano, M.; Moriwaki, H.; Seishima, M. Lack of Internerleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb. Vasc. Biol., 2003, 23(4), 656-660.
110. Rajavashisth, T. B.; Xu, X. P.; Jovinge, S.; Meisel, S.; Xu, X. O.; Chai, N. N.; Fishbein, M. C.; Kaul, S.; Cercek, B.; Sharifi, B.; Shah, P. K. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation, 1999, 99(24), 3103-3109.
111. Kamari, Y.; Werman-Venkert, R.; Shaish, A.; Werman, A.; Harari, A.; Gonen, A.; Voronov, E.; Grosskopf, I.; Sharabi, Y.; Grossman, E.; Iwakura, Y.; Dinarello, C. A.; Apte, R. N.; Harats, D. Differential role and tissue specificity of Internerleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis, 2007, 195(1), 31-38.
112. Voronov, E.; Shouval, D. S.; Krelin, Y.; Cagnano, E.; Benharroch, D.; Iwakura, Y.; Dinarello, C. A.; Apte, R. N. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA, 2003,100 (5), 2645-50.
113. Nicklin, M. J.; Hughes, D. E.; Barton, J. L.; Ure, J. M.; Duff, G. W. Arterial inflammation in mice lacking the Internerleukin 1 receptor antagonist gene. J. Exp. Med. 2000,191 (2), 303-12.
114. Isoda, K.; Ohsuzu, F. The effect of Internerleukin-1 receptor antagonist on arteries and cholesterol metabolism. J. Atheroscler Thromb., 2006, 13(1), 21-30.
115. Chamberlain, J.; Evans, D.; King, A.; Dewberry, R.; Dower, S.; Crossman, D.; Francis, S. Internerleukin-1beta and signaling of Internerleukin-1 in vascular wall and circulating cells modulates the extent of neoInternima formation in mice. Am. J. Pathol., 2006, 168(4), 1396-1403.
116. Guillen, I.; Blanes, M.; Gomez-Lechon, M. J.; Castell, J. V. Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am. J. Physiol., 1995, 269 (2 Pt 2), R229-235.
117. Schwager, I.; Jungi, T. W. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood, 1994, 83(1), 152-160.
118. Bujak, M.; Dobaczewski, M.; Chatila, K.; Mendoza, L. H.; Li, N.; Reddy, A.; Frangogiannis, N. G. Internerleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am. J. Pathol., 2008, 173(1), 57-67.
119. Macfelda, K.; Weiss, T. W.; Kaun, C.; Breuss, J. M.; Zorn, G.; Oberndorfer, U.; Voegele-Kadletz, M.; Huber-Beckmann, R.; Ullrich, R.; Binder, B. R.; Losert, U. M.; Maurer, G.; Pacher, R.; Huber, K.; Wojta, J. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators Internerleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J. Mol. Cell. Cardiol.,. 2002, 34(12), 1681-1691.
120. Matsumori, A.; Yamada, T.; Suzuki, H.; Matoba, Y.; Sasayama, S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J., 1994, 72(6), 561-566.
121. Finkel, M. S.; Oddis, C. V.; Jacob, T. D.; Watkins, S. C.; Hattler, B. G.; Simmons, R. L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science, 1992, 257(5068), 387-389.
122. Isoda, K.; Shiigai, M.; Ishigami, N.; Matsuki, T.; Horai, R.; Nishikawa, K.; Kusuhara, M.; Nishida, Y.; Iwakura, Y.; Ohsuzu, F. Deficiency of Internerleukin-1 receptor antagonist promotes neoInternimal formation after injury. Circulation, 2003, 108(5), 516-518.
123. Merhi-Soussi, F.; Kwak, B. R.; Magne, D.; Chadjichristos, C.; Berti, M.; Pelli, G.; James, R. W.; Mach, F.; Gabay, C. Internerleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res., 2005,66 (3), 583-593.
124. Meier, C. A.; Bobbioni, E.; Gabay, C.; Assimacopoulos-Jeannet, F.; Golay, A.; Dayer, J. M. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J. Clin. Endocrinol. Metab., 2002, 87(3), 1184-1188.
125. Francis, S. E.; Camp, N. J.; Dewberry, R. M.; Gunn, J.; Syrris, P.; Carter, N. D.; Jeffery, S.; Kaski, J. C.; Cumberland, D. C.; Duff, G. W.; Crossman, D. C. Internerleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation, 1999, 99(7), 861-866.
126. Kastrati, A.; Koch, W.; Berger, P. B.; Mehilli, J.; Stephenson, K.; Neumann, F. J.; von Beckerath, N.; Bottiger, C.; Duff, G. W.; Schomig, A. Protective role against restenosis from an Internerleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J. Am. College Cardiol., 2000, 36(7), 2168-2173.
127. Patti, G.; D'Ambrosio, A.; Dobrina, A.; Dicuonzo, G.; Giansante, C.; Fiotti, N.; Abbate, A.; Guarnieri, G.; Di Sciascio, G. Internerleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. J. Thromb. Thrombolysis, 2002, 14(2), 139-143.
128. Patti, G.; Mega, S.; Pasceri, V.; Nusca, A.; Giorgi, G.; Zardi, E. M.; D'Ambrosio, A.; Dobrina, A.; Di Sciascio, G. Internerleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin. Cardiol., 2005, 28(4), 193-196.
129. Patti, G.; D'Ambrosio, A.; Mega, S.; Giorgi, G.; Zardi, E. M.; Zardi, D. M.; Dicuonzo, G.; Dobrina, A.; Di Sciascio, G. Early Internerleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J. Am. College Cardiol., 2004, 43(1), 35-38.
130. Suzuki, K.; Murtuza, B.; Smolenski, R. T.; Sammut, I. A.; Suzuki, N.; Kaneda, Y.; Yacoub, M. H. Overexpression of Internerleukin-1 receptor antagonist provides cardioprotection against ischemiareperfusion injury associated with reduction in apoptosis. Circulation, 2001, 104(12 Suppl 1), I308-13I3.
131. Grothusen, C.; Hagemann, A.; Attmann, T.; Braesen, J.; Broch, O.; Cremer, J.; Schoettler, J. Impact of an Internerleukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia/reperfusion injury. Scientific World J., 2012, 2012, 737585.
132. Abbate, A.; Salloum, F. N.; Vecile, E.; Das, A.; Hoke, N. N.; Straino, S.; Biondi-Zoccai, G. G.; Houser, J. E.; Qureshi, I. Z.; Ownby, E. D.; Gustini, E.; Biasucci, L. M.; Severino, A.; Capogrossi, M. C.; Vetrovec, G. W.; Crea, F.; Baldi, A.; Kukreja, R. C.; Dobrina, A. Anakinra, a recombinant human Internerleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation, 2008, 117(20), 2670-2683.
133. Murtuza, B.; Suzuki, K.; Bou-Gharios, G.; Beauchamp, J. R.; Smolenski, R. T.; Partridge, T. A.; Yacoub, M. H. Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. Proc. Natl. Acad. Sci. USA, 2004, 101(12), 4216-4221.
134. Abbate, A.; Kontos, M. C.; Grizzard, J. D.; Biondi-Zoccai, G. G.; Van Tassell, B. W.; Robati, R.; Roach, L. M.; Arena, R. A.; Roberts, C. S.; Varma, A.; Gelwix, C. C.; Salloum, F. N.; Hastillo, A.; Dinarello, C. A.; Vetrovec, G. W. Internerleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am. J. Cardiol., 2010, 105(10), 1371-1377 e1.
135. Crossman, D. C.; Morton, A. C.; Gunn, J. P.; Greenwood, J. P.; Hall, A. S.; Fox, K. A.; Lucking, A. J.; Flather, M. D.; Lees, B.; Foley, C. E. Investigation of the effect of Internerleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials, 2008, 9, 8.
136. Ikonomidis, I.; Lekakis, J. P.; Nikolaou, M.; Paraskevaidis, I.; Andreadou, I.; Kaplanoglou, T.; Katsimbri, P.; Skarantavos, G.; Soucacos, P. N.; Kremastinos, D. T. Inhibition of Internerleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation, 2008, 117(20), 2662-2669.